Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynecology,Oncology
Reference18 articles.
1. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group Study (GOG-254);Chan;Gynecol. Oncol.,2018
2. Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775);Colombo;Ann. Oncol.,2021
3. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary;Crotzer;Gynecol. Oncol.,2007
4. Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9);Esposito;Oncology,2014
5. Gien, L., Enseroo, D., Block, M., 2022. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: an NRG Oncology Study (NRG-GY016). Presented at: 2022 Annual Global Meeting of the International Gynecologic Cancer Society, Sep. 2022.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series;Gynecologic Oncology Reports;2024-06
2. Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study;International Journal of Gynecologic Cancer;2024-04-24
3. Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy;Journal of Cancer Research and Practice;2024-01
4. Primary ovarian insufficiency associated with lenvatinib therapy in a patient with hepatocellular carcinoma: A case report;Oncology Letters;2023-08-31
5. Immuntherapie in Kombination mit der Chemotherapie;InFo Hämatologie + Onkologie;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3